Board of Directors
Mr. Doyle has served on our board of directors since November 2012. Mr. Doyle is the Chief Executive Officer at Castlight Health. During 2016, Mr. Doyle served as President and Chief Operating Officer of Castlight. He joined the company in 2012 as its Chief Financial Officer. Mr. Doyle served as Achaogen’s Chief Operating Officer from August 2009 to November 2009 and from February 2011 to November 2012, and as its Chief Financial Officer from November 2009 to February 2011. Prior to joining Achaogen, Mr. Doyle was Vice President of Finance and Corporate Planning at Genentech, from 2007 to 2009.
Mr. Doyle is a member of the 2012 class of Henry Crown Fellows at the Aspen Institute. He has a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo and an M.B.A. from the University of California, Berkeley.
Dr. Fischbach has served on Achaogen’s board of directors since November 2015. In 2017, Dr. Fischbach joined Stanford University as an Associate Professor in the Department of Bioengineering and as a member of Stanford ChEM-H, an interdisciplinary research institute that uses chemistry, engineering and medicine to improve human health. Dr. Fischbach’s laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Prior to Stanford, he was an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF, and prior to that he spent two years as an independent fellow at Massachusetts General Hospital. He is a member of the California Institute for Quantitative Biosciences (QB3). Dr. Fischbach is a recipient of the NIH Director's Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, and a Glenn Award for Research in Biological Mechanisms of Aging. Dr. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007 and earned his A.B. in Biochemistry from Harvard.
Dr. Fischbach is a member of the scientific advisory boards of NGM Biopharmaceuticals, Cell Design Labs, and Indigo Agriculture, and is a co-founder of Revolution Medicines.
Ms. Gilbert has served on Achaogen’s board of directors since January 2017. Since 2008, Ms. Gilbert has served as Senior Vice President, Chief Legal Officer of Ironwood Pharmaceuticals, providing leadership and oversight and establishing the company’s compliance function as Ironwood grew from a privately-held, research-based organization to a publicly-traded, fully-integrated commercial biotechnology company. Ms. Gilbert brings significant s trategic leadership and two decades of experience navigating biopharmaceutical companies through transformational change, as well as expertise in corporate transactions, corporate governance, employment law and legal and operational issues relevant to launching new medicines into specialty and primary care markets. Prior to joining Ironwood, Ms. Gilbert was Vice President, Deputy General Counsel at Cubist Pharmaceuticals from 2002 to 2008, where she supported the launch of Cubist’s first acute care antibiotic. From 1991 to 2001, Ms. Gilbert served as Corporate Counsel at Genzyme Corporation. Ms. Gilbert began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law.
Ms. Gilbert holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University.
Dr. Hillan has served on Achaogen’s board of directors since October 2011. Dr. Hillan joined Achaogen in April 2011 as Chief Medical Officer and was appointed Chief Executive Officer in October 2011. Dr. Hillan became President, R&D and President of Achaogen in January 2018. Prior to joining Achaogen, Dr. Hillan held leadership roles at Genentech (acquired by Roche in 2009) from August 1994 to April 2011. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. Dr. Hillan has served on the board of directors of Zymeworks, a publicly traded biotech company, since February 2017. He served on the board of directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
Dr. Lieginger has served on Achaogen’s board of directors since March 2015. Dr. Lieginger has most recently served as Senior Vice President, Managed Care and Customer Operations at Genentech from 2004 to July 2014, as well as Director of the Genentech Foundation from 2010 to 2012. He joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech’s Commercial Leadership Committee. Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales.
Dr. Lieginger completed his residency in clinical pharmacy at the University of California in San Francisco, served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine. Dr. Lieginger served on the Board of Trustees at University of the Sciences in Philadelphia from 2013 to 2017.
Dr. Roberts has served on Achaogen’s board of directors since August 2004, and he has served as our Chairman since December 2009. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is currently on the board of directors of three publicly traded companies: Zeltiq Aesthetics, Castlight Health, and Vitae Pharmaceuticals, Inc. He also serves on the board of directors of several private companies and previously served on the board of directors of publicly traded Athenahealth, Inc., XenoPort, Inc., and Sirna Therapeutics, Inc. He has a B.A. in Chemistry from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.
Mr. Smither has served on Achaogen’s board of directors since December 2013. Mr. Smither has served as Chief Financial Officer of Sienna Biopharmaceuticals since April 2018. From November 2017 to April 2018, Mr. Smither served as Interim CFO for Kite Pharma, a subsidiary of Gilead Sciences. From January 2016 to July 2017, Mr. Smither served as Chief Financial Officer of Unity Biotechnology. From January 2016 to March 2017, Mr. Smither also served as Chief Financial Officer of Sienna Biopharmaceuticals a biotechnology company. Prior to that, Mr. Smither was the Chief Financial Officer of Kythera Biopharmaceuticals from November 2007 until it was acquired by Allergan in October 2015 for $2.1 billion. As CFO of Kythera, he was responsible for finance during multiple private and public capital raising rounds including the Company’s IPO and subsequent follow-on offerings, licensing and repurchasing of the international rights of its lead product to Bayer, and placement of several venture debt facilities. From 1998 to 2007, Mr. Smither held various positions at Amgen. Including Vice President of Finance and Administration of Amgen’s European Division, Head of Internal Audit, and Executive Director of Corporate Accounting. Prior to joining Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young had served as the Chief Financial Officer of several early stage companies.
Mr. Smither received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.
Mr. Stea has served on our board of directors since June 2015. From September 2016 to January 2018, Mr. Stea held a consulting role to assist La Jolla Pharmaceuticals in preparing for the commercialization of their first drug, Angiotensin II. Prior to this, Mr. Stea served as Senior Vice President of Commercial Operations for Cubist from 2009 to February 2015, leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa and Sivextro. Prior to this, Mr. Stea served as Cubist’s Vice President, Sales and Marketing from 2007 to 2009. Having joined Cubist as an original member of the commercial organization, Mr. Stea served as Cubist’s Vice President of Sales from 2005 to 2007 and Executive Director of Sales from 2002 to 2005. Mr. Stea also served as a member of the Cubist Operating Committee from 2009 to February 2015, which was responsible for resource allocation, company strategy, risk management and compliance, among other responsibilities. Mr. Stea previously held leadership positions at Amgen from 1988 to 1997, where he was the first employee of its sales organization, responsible for the launch of Epogen and Neupogen.
Mr. Stea holds a Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s Executive Education program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology.